• Bismuth Subsalicylate: Precision in GI Research & Apoptosis

  2026-08-03

  Discover how Bismuth Subsalicylate empowers gastrointestinal disorder research and apoptosis assay development. This deep dive explores unique mechanistic insights and advanced protocol considerations, setting it apart in the field.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-08-03

  This study details the rational design and characterization of new allosteric inhibitors targeting pyruvate dehydrogenase kinase 4 (PDK4), presenting compound 8c as a metabolically stable and orally viable candidate that improves glucose tolerance and mitigates allergic and cancer-related processes in preclinical models. These findings offer a new therapeutic scaffold for metabolic, allergic, and oncological disorders involving PDK4 dysregulation.

• Cy5 NHS ester(Et): Technical Guide for Fluorescent Labeling

  2026-08-02

  Cy5 NHS ester(Et) enables efficient, water-soluble fluorescent labeling of primary amines in proteins and biomolecules, supporting precise detection in immunofluorescence, flow cytometry, and fluorescence microscopy workflows. It is not suitable for ethanol-based protocols or for situations requiring long-term storage of dissolved dye solutions. This technical guide provides actionable parameters and troubleshooting steps for reliable use.

• PA-824: Advanced Protocols for Mycobacterium tuberculosis Re

  2026-08-01

  Leverage PA-824, a potent bicyclic nitroimidazole derivative, to streamline tuberculosis research with reproducible, dual-action bactericidal workflows. This guide delivers actionable protocol enhancements, synergy-driven assay strategies, and troubleshooting insights grounded in the latest mechanistic evidence.

• Torin2: Precision mTOR Inhibitor Optimizing Cancer Research

  2026-07-31

  Torin2 sets a new standard among mTOR inhibitors, offering exquisite selectivity and robust performance in both in vitro and in vivo cancer models. This guide details optimized protocols, troubleshooting strategies, and practical insights that translate recent mechanistic breakthroughs into high-impact experimental design.

• Antipyrine in CNS Drug Discovery: Applied Workflows & Troubl

  2026-07-31

  Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) is a gold standard for benchmarking blood-brain barrier (BBB) permeability and pharmacokinetic workflows. This article details stepwise protocols and advanced strategies to maximize reproducibility and data quality in CNS drug research using high-purity Antipyrine from APExBIO.

• Salvianolic acid B: Optimizing Pulmonary Fibrosis Research W

  2026-07-30

  Salvianolic acid B (Dan Shen Suan B) stands out as a high-purity, research-grade antifibrotic agent, uniquely targeting lysyl hydroxylase 2 to disrupt collagen cross-linking in pulmonary fibrosis models. This guide translates the latest mechanistic advances and protocol optimizations into actionable workflows for translational scientists.

• Nitroaromatic Nannocystin Targets AKT1 for Colorectal Cancer

  2026-07-30

  A recent study details the total synthesis and in vivo anticancer efficacy of a nitroaromatic nannocystin derivative that selectively targets AKT1 in colorectal cancer models. This work advances the field by demonstrating potent inhibition of tumor growth and providing mechanistic insight into targeted chemotherapeutic strategies.

• DOPE Lipid Advances: Bridging Fungal Ferroptosis and Deliver

  2026-07-29

  This article unpacks the mechanistic and translational power of 1,2-Dioleoyl-sn-glycero-3-PE (DOPE), spotlighting its dual roles as a membrane fusion enhancer in nucleic acid delivery and as a modulator of lipid peroxidation in fungal ferroptosis. By integrating direct evidence from recent studies—including restoration of pathogenicity in Magnaporthe oryzae via exogenous DOPE and linking advanced lipidomics with real-world transfection strategies—this piece offers actionable guidance for translational researchers and positions APExBIO’s DOPE as a cornerstone in cutting-edge lipid nanoparticle and fungal pathogenesis research.

• SP1/ADAM10/DRP1 Axis Drives EC-SMC Crosstalk in Hypoxia PH

  2026-07-29

  This study uncovers the pivotal role of the SP1/ADAM10/DRP1 signaling axis in mediating intercellular communication between endothelial and smooth muscle cells during hypoxia-induced pulmonary hypertension (HPH). By delineating how ADAM10 secreted from endothelial cells influences smooth muscle cell proliferation and apoptosis via downstream pathways, the research highlights new molecular targets for potential therapeutic intervention in HPH.

• In Silico Peptide Screening Targets β-Lactamase in E. coli

  2026-07-28

  The reference study introduces MDockPeP2_VS, a new automated computational platform for large-scale discovery of protein-binding peptides. By enabling practical in silico screening against β-lactamase, the method accelerates peptide inhibitor development for combating antibiotic resistance.

• Bile Acid Retention Disrupts Antigen Presentation in MASH-HC

  2026-07-28

  This study reveals that bile acid accumulation in metabolic dysfunction-associated steatohepatitis hepatocellular carcinoma (MASH-HCC) suppresses NLRC5-mediated MHC-I antigen presentation, facilitating immune escape. By uncovering the GPR120-bile acid-NLRC5 axis, the research highlights new therapeutic strategies for sensitizing MASH-HCC to immunotherapy.

• Resazurin Cell Viability Assay Kit: Sensitivity & Utility in

  2026-07-27

  The Resazurin Cell Viability Assay Kit enables sensitive, non-toxic quantification of live cells across diverse biological contexts. This cell viability assay supports both fluorescence and colorimetric detection, offering high-throughput compatibility and superior sensitivity compared to conventional methods.

• MAPK10-Mediated KRT16 Degradation Suppresses NSCLC Metastasi

  2026-07-27

  This study uncovers a phosphorylation-dependent pathway in which MAPK10 suppresses non-small cell lung cancer (NSCLC) metastasis by promoting the ubiquitination and degradation of keratin 16 (KRT16). The findings establish the MAPK10/KRT16/RNF213 axis as a mechanistically defined therapeutic target and prognostic marker for NSCLC, offering new directions for personalized intervention.

• Dacarbazine: Mechanistic Precision and Strategic Impact in T

  2026-07-26

  Explore how Dacarbazine’s DNA alkylation mechanism, validated by modern in vitro methodologies, is reshaping translational cancer research. This article integrates mechanistic detail, practical protocol guidance, and competitive insight, while positioning APExBIO’s Dacarbazine as a benchmark for reproducibility and innovation in the treatment of malignant melanoma, Hodgkin lymphoma, and sarcoma.

16737 records 1/1116 page Next 12345 下5页 Last page